Source 1review2026MED
Toolkit/gp350-directed CAR recognition strategy
gp350-directed CAR recognition strategy
Also known as: gp350
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Explicitly named in the anchor review as an autologous gp350-targeted CAR-T product in clinical development for EBV-positive lymphomas. High-priority EBV antiviral/oncovirology target with direct CAR-T relevance.
Usefulness & Problems
Why this is useful
This strategy uses EBV gp350 as the target antigen for CAR-T recognition. The supplied evidence ties gp350 to both preclinical validation and a named clinical-development product.; building EBV-targeted CAR recognition modules; targeting gp350 in EBV-associated CAR-T strategies
Source:
This strategy uses EBV gp350 as the target antigen for CAR-T recognition. The supplied evidence ties gp350 to both preclinical validation and a named clinical-development product.
Source:
building EBV-targeted CAR recognition modules
Source:
targeting gp350 in EBV-associated CAR-T strategies
Problem solved
It addresses the need for a directly actionable EBV target in CAR-T design.; provides a named EBV target for CAR design
Source:
It addresses the need for a directly actionable EBV target in CAR-T design.
Source:
provides a named EBV target for CAR design
Problem links
provides a named EBV target for CAR design
LiteratureIt addresses the need for a directly actionable EBV target in CAR-T design.
Source:
It addresses the need for a directly actionable EBV target in CAR-T design.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
car-mediated antigen recognitionTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
It requires a gp350-targeting CAR recognition module. The payload does not provide further build details.; requires a gp350-targeting recognition module in a CAR construct
The supplied evidence does not show whether gp350 targeting is preferable to other EBV targets in all settings.; the supplied payload does not provide detailed construct architecture or comparative review analysis
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review explicitly names gp350 and LMP1 as EBV CAR target leads, and names BRG01 as a gp350-targeted autologous CAR-T product in clinical development.
The review explicitly names HBsAg-related and PreS1-related HBV CAR strategies, including 4D06 and 4D08 as HBV-directed binder leads.
The review explicitly names VRC01, 3BNC117, and 10-1074 as HIV broadly neutralizing antibody-derived CAR binder leads.
Within the supplied evidence, the strongest explicitly supported antiviral CAR design leads are HIV Env/bNAb-based CARs, HBV HBsAg-directed CARs, and EBV gp350/LMP1-directed CARs.
The review explicitly names CCR5-locus knock-in and C34-CXCR4 as HIV-protective engineering features relevant to antiviral CAR-T design.
Approval Evidence
1 source1 linked approval claimfirst-pass slug gp350-directed-car-recognition-strategy
Explicitly named in the anchor review as an autologous gp350-targeted CAR-T product in clinical development for EBV-positive lymphomas. High-priority EBV antiviral/oncovirology target with direct CAR-T relevance.
Source:
component summarysupports
The review explicitly names gp350 and LMP1 as EBV CAR target leads, and names BRG01 as a gp350-targeted autologous CAR-T product in clinical development.
Source:
Comparisons
Source-stated alternatives
The payload explicitly names LMP1 as another EBV CAR target.
Source:
The payload explicitly names LMP1 as another EBV CAR target.
Source-backed strengths
explicitly identified as a high-priority EBV CAR target in the supplied evidence; linked to both preclinical and clinical-development leads in the supplied evidence
Source:
explicitly identified as a high-priority EBV CAR target in the supplied evidence
Source:
linked to both preclinical and clinical-development leads in the supplied evidence
Compared with LMP1-directed CAR recognition strategy
The payload explicitly names LMP1 as another EBV CAR target.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly identified as a high-priority EBV CAR target in the supplied evidence; linked to both preclinical and clinical-development leads in the supplied evidence.
Relative tradeoffs: the supplied payload does not provide detailed construct architecture or comparative review analysis.
Source:
The payload explicitly names LMP1 as another EBV CAR target.
Ranked Citations
- 1.